JIANG Ru Hong 姜儒鴻

Dr. JIANG Ru Hong

  • Chairman, CEO and President of ASC Therapeutics Inc.

Dr. Ruhong Jiang, is CEO of ASC Therapeutics Inc. – a global leading company in gene therapy and allogenic cell therapy. Under his leadership, the company has successfully moved two programs into clinical stage within two years. Ruhong has held a variety of technical and managerial roles in several biotechnology/biopharmaceutical companies. Prior to starting Applied StemCell, he was general manager of MicuRx(Shanghai)Pharmaceutical, Inc. a California‐based biopharmaceutical company and he set up its entire China operation. From 2005‐2007, Dr. Jiang was head of the Pharmacogenetics Program at Stanford Research Institute International (SRI) where he managed multiple pharmacogenetic and molecular genetics projects with multi‐million annual budgets. Before relocating to California, Dr. Jiang was pharmacogenomics consultant at Boehringer Ingelheim Pharmaceuticals and served as senior scientist, then director of project management at Genaissance Pharmaceuticals from 2000‐2004 where he played an important role in biomarker discovery, pharmacogenetics and clinical bioinformatics, diagnostic product development, alliance management and business development. Dr. Jiang graduated from Fudan University with a B.S. degree in biology and received his M.S. degree in reproductive biology from China Agricultural University and a Ph.D. degree in Genetics from Oklahoma state University in 1997. He later went to Baylor College of Medicine where he furthered his education as a postdoctoral fellow in Dr. Douglas Burrin’s lab. Dr. Jiang has published more than 40 articles in the fields of human genetics, pharmacogenetics and disease animal models. In addition, Ruhong has a deep interest in the science, ethics and societal issues of personalized medicine, regenerative medicine and global health. His demonstrated leadership has led to an established track record of success; especially in the areas of biomarker‐based molecular assays or diagnosis, CRO service, and drug research and development.